-
Posted by
Two Blokes Jun 23 -
Filed in
Stock
-
4 views
– Broad label inclusive of all ages and disease severities – – Launch to be initiated in Germany – WARREN, N.J. , June 23, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Sephience\u2122 (sepiapterin) was granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU).
